CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 20 other locations
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....
Phase 2, Phase 3
Salt Lake City, Utah, United States and 61 other locations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
Salt Lake City, Utah, United States and 80 other locations
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM).The following intervent...
Phase 2
Salt Lake City, Utah, United States and 6 other locations
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).The drugs involved in ...
Phase 2
Salt Lake City, Utah, United States and 11 other locations
are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...
Phase 3
Salt Lake City, Utah, United States and 22 other locations
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma...
Phase 1
Salt Lake City, Utah, United States and 7 other locations
designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma...
Phase 1
Salt Lake City, Utah, United States
* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM...
Phase 1
Salt Lake City, Utah, United States and 7 other locations
patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation....
Phase 2
Salt Lake City, Utah, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal